CytomX Therapeutics, Inc. (CTMX)

Market Cap	69.65M
Revenue (ttm)	126.62M
Net Income (ttm)	13.83M
Shares Out	78.26M
EPS (ttm)	0.16
PE Ratio	5.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	494,230
Open	0.890
Previous Close	0.867
Day's Range	0.860 - 0.895
52-Week Range	0.833 - 5.850
Beta	1.06
Analysts	Buy
Price Target	5.77 (+548.32%)
Earnings Date	Nov 7, 2024

About CTMX

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 122
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX
• Website: https://www.cytomx.com

Financial Performance

In 2023, CytomX Therapeutics's revenue was $101.21 million, an increase of 90.38% compared to the previous year's $53.16 million. Losses were -$569,000, -99.43% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is $5.77, which is an increase of 548.32% from the latest price.

Price Target

$5.77

(548.32% upside)

Analyst Consensus: Buy